PrEP variation ‘safe and well-tolerated in women’

Pre-exposure prophylaxis (PrEP) regimens containing the antiretroviral drug maraviroc have been found to be safe and well-tolerated in women at risk of HIV infection.

This is compared with mtricitabine-tenofovir disoproxil fumarate, sold by the brand name Truvada, according to results from a phase two trial published in Annals of Internal Medicine.

Dr Roy M Gulick, from Weill Cornell Medicine, and colleagues wrote that “effective strategies to prevent HIV acquisition among women are urgently needed, yet studies of HIV PrEP in women have shown conflicting results.”

Now, they found that maraviroc, which is a CCR5 antagonist HIV entry inhibitor approved for HIV treatment, is a viable candidate drug for HIV PrEP.

Gulick and colleagues conducted a phase two controlled, double-blinded study to determine the safety and tolerability of maraviroc-containing PrEP in women at risk of HIV infection from one of 12 United States clinical research sites of the HIV Prevention Trials Network and AIDS Clinical Trials Group.

They found that it was “generally safe and well-tolerated”.ADNFCR-2094-ID-801839387-ADNFCR